press conference
Roche is growing – despite declining Covid business
The rapid Covid tests no longer generate large sales for Roche. Roche boss Thomas Schinecker said that this could be easily compensated for in 2023. The company will provide information on the annual balance sheet at a media conference on Thursday.
Roche is not just growing in terms of buildings: CEO Thomas Schinecker at the media conference on the 2023 annual balance sheet.
Images: zvg/Georgios Kefalas/EPA
The Basel-based pharmaceutical company Roche sold slightly more medicines and diagnostic tests last year. Sales rose 1 percent at constant exchange rates to 58.7 billion francs. The company wrote in a statement that this more than compensated for the declining sales from the Covid business – Roche produces rapid tests, for example.
“In total, we made up for a loss in sales of around 6.4 billion francs – which corresponds to more than 10 percent of our sales,” said Roche boss Thomas Schinecker in a statement. The company was left with a profit of 19.2 billion francs, which corresponds to a loss of 1 percent. More research costs weighed on profits.
Roche boss Thomas Schinecker earned 9.6 million francs last year, and board chairman Severin Schwan earned 4.5 million. Compared to its competitor Novartis, the wages are more modest: On Wednesday, the second Basel pharmaceutical giant announced that it would pay its CEO Vas Narasimhan 16.2 million. (mpa)